Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,449.42
    +281.35 (+0.70%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,312.30
    +320.62 (+0.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,541.25
    +10.65 (+0.70%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Is Endo International (ENDP) a Great Stock for Value Investors?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Endo International plc ENDP stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Endo International has a trailing twelve months PE ratio of 5.1, as you can see in the chart below:



This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.1. If we focus on the stock’s long-term PE trend, the current level puts Endo International’s current PE ratio somewhat below its midpoint (which is 7.0) over the past three years.



Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 90.0. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.



We should also point out that Endo International has a forward PE ratio (price relative to this year’s earnings) of 6.1, so it is fair to expect an increase in the company’s share price in the near future.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Endo International has a P/S ratio of about 1.2. This is substantially lower than the S&P 500 average, which comes in at 3.5 right now. Also, as we can see in the chart below, this is way below the highs for this stock in particular over the past few years.



If anything, this suggests some level of undervalued trading—at least compared to historical norms.   

Broad Value Outlook

In aggregate, Endo International currently has a Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes ENDP a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the P/CF ratio (another great indicator of value) comes in at 1.9, which is much better than the industry average of 11.3. Clearly, ENDP is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Endo International might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of D and a Momentum score of C. This gives ENDP a VGM score—or its overarching fundamental grade—of B. (You can read more about the Zacks Style Scores here >>)

ADVERTISEMENT

Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen one estimate go higher in the past sixty days and six lower, while the full year estimate has seen 11 upward and no downward revisions in the same time period.

This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate has fallen nearly 1.7% in the past two months, while the full year estimate has risen about 8.8%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Endo International plc Price and Consensus

 

Endo International plc Price and Consensus | Endo International plc Quote

This mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.

Bottom Line

Endo International is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a good industry rank (top 43% out of more than 250 industries) further supports the growth potential of the stock. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:



So, value investors might want to wait for estimates, analyst sentiment and industry trends to turn favorable in this name first, but once that happens, this stock could be a compelling pick.

5 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.

Click to see them right now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Endo International plc (ENDP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research